The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative Sciences & eXtellia, and his teams shared their scientific expertise in CRISPR/Cas9 technology and clinical development experience to the members in Corn lab.
One of our postdocs, Matthias Muhar, secured a group leader position at the Max Planck Institute of Molecular Biology and Genetics in Dresden, Germany in November...
We are delighted to announce that Fedor has successfully defended his PhD. During his doctoral research, Fedor demonstrated remarkable dedication and perseverance,...
We are happy to announce that Seba has successfully completed his PhD, built on passionate and persistent research into synthetic lethality in the DNA damage...
Questions and/or comments about Corn Lab and its activities may be addressed to:
